Doxercalciferol

BreastfeedingPediatric
  • TRADE NAME: Hectorol (Genzyme)
  • INDICATIONS: Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
  • CLASS: Vitamin D receptor agonist
  • HALF-LIFE: 32–37 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aminoglutethimide, Cholestyramine, Erythromycin, Ketoconazole, Magnesium-containing antacids, Mineral oil, Phenobarbital

PREGNANCY CATEGORY: B

Contra-indicated in patients with a tendency towards hypercalcemia or current evidence of vitamin D toxicity.

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top